Copyright Reports & Markets. All rights reserved.

Global Acinetobacter Infections Treatment Market Growth 2019-2024

Request for Sample of this report
Buy now

Table of Contents

    2019-2024 Global Acinetobacter Infections Treatment Consumption Market Report

      1 Scope of the Report

      • 1.1 Market Introduction
      • 1.2 Research Objectives
      • 1.3 Years Considered
      • 1.4 Market Research Methodology
      • 1.5 Economic Indicators
      • 1.6 Currency Considered

      2 Executive Summary

      • 2.1 World Market Overview
        • 2.1.1 Global Acinetobacter Infections Treatment Consumption 2014-2024
        • 2.1.2 Acinetobacter Infections Treatment Consumption CAGR by Region
      • 2.2 Acinetobacter Infections Treatment Segment by Type
        • 2.2.1 Sulbactam
        • 2.2.2 Carbapenems
        • 2.2.3 Aminoglycosides
        • 2.2.4 Polymyxins
        • 2.2.5 Tetracyclines
        • 2.2.6 Others
      • 2.3 Acinetobacter Infections Treatment Consumption by Type
        • 2.3.1 Global Acinetobacter Infections Treatment Consumption Market Share by Type (2014-2019)
        • 2.3.2 Global Acinetobacter Infections Treatment Revenue and Market Share by Type (2014-2019)
        • 2.3.3 Global Acinetobacter Infections Treatment Sale Price by Type (2014-2019)
      • 2.4 Acinetobacter Infections Treatment Segment by Application
        • 2.4.1 Application I
        • 2.4.2 Application II
      • 2.5 Acinetobacter Infections Treatment Consumption by Application
        • 2.5.1 Global Acinetobacter Infections Treatment Consumption Market Share by Application (2014-2019)
        • 2.5.2 Global Acinetobacter Infections Treatment Value and Market Share by Application (2014-2019)
        • 2.5.3 Global Acinetobacter Infections Treatment Sale Price by Application (2014-2019)

      3 Global Acinetobacter Infections Treatment by Players

      • 3.1 Global Acinetobacter Infections Treatment Sales Market Share by Players
        • 3.1.1 Global Acinetobacter Infections Treatment Sales by Players (2017-2019)
        • 3.1.2 Global Acinetobacter Infections Treatment Sales Market Share by Players (2017-2019)
      • 3.2 Global Acinetobacter Infections Treatment Revenue Market Share by Players
        • 3.2.1 Global Acinetobacter Infections Treatment Revenue by Players (2017-2019)
        • 3.2.2 Global Acinetobacter Infections Treatment Revenue Market Share by Players (2017-2019)
      • 3.3 Global Acinetobacter Infections Treatment Sale Price by Players
      • 3.4 Global Acinetobacter Infections Treatment Manufacturing Base Distribution, Sales Area, Product Types by Players
        • 3.4.1 Global Acinetobacter Infections Treatment Manufacturing Base Distribution and Sales Area by Players
        • 3.4.2 Players Acinetobacter Infections Treatment Products Offered
      • 3.5 Market Concentration Rate Analysis
        • 3.5.1 Competition Landscape Analysis
        • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
      • 3.6 New Products and Potential Entrants
      • 3.7 Mergers & Acquisitions, Expansion

      4 Acinetobacter Infections Treatment by Regions

      • 4.1 Acinetobacter Infections Treatment by Regions
        • 4.1.1 Global Acinetobacter Infections Treatment Consumption by Regions
        • 4.1.2 Global Acinetobacter Infections Treatment Value by Regions
      • 4.2 Americas Acinetobacter Infections Treatment Consumption Growth
      • 4.3 APAC Acinetobacter Infections Treatment Consumption Growth
      • 4.4 Europe Acinetobacter Infections Treatment Consumption Growth
      • 4.5 Middle East & Africa Acinetobacter Infections Treatment Consumption Growth

      5 Americas

      • 5.1 Americas Acinetobacter Infections Treatment Consumption by Countries
        • 5.1.1 Americas Acinetobacter Infections Treatment Consumption by Countries (2014-2019)
        • 5.1.2 Americas Acinetobacter Infections Treatment Value by Countries (2014-2019)
      • 5.2 Americas Acinetobacter Infections Treatment Consumption by Type
      • 5.3 Americas Acinetobacter Infections Treatment Consumption by Application
      • 5.4 United States
      • 5.5 Canada
      • 5.6 Mexico
      • 5.7 Key Economic Indicators of Few Americas Countries

      6 APAC

      • 6.1 APAC Acinetobacter Infections Treatment Consumption by Countries
        • 6.1.1 APAC Acinetobacter Infections Treatment Consumption by Countries (2014-2019)
        • 6.1.2 APAC Acinetobacter Infections Treatment Value by Countries (2014-2019)
      • 6.2 APAC Acinetobacter Infections Treatment Consumption by Type
      • 6.3 APAC Acinetobacter Infections Treatment Consumption by Application
      • 6.4 China
      • 6.5 Japan
      • 6.6 Korea
      • 6.7 Southeast Asia
      • 6.8 India
      • 6.9 Australia
      • 6.10 Key Economic Indicators of Few APAC Countries

      7 Europe

      • 7.1 Europe Acinetobacter Infections Treatment by Countries
        • 7.1.1 Europe Acinetobacter Infections Treatment Consumption by Countries (2014-2019)
        • 7.1.2 Europe Acinetobacter Infections Treatment Value by Countries (2014-2019)
      • 7.2 Europe Acinetobacter Infections Treatment Consumption by Type
      • 7.3 Europe Acinetobacter Infections Treatment Consumption by Application
      • 7.4 Germany
      • 7.5 France
      • 7.6 UK
      • 7.7 Italy
      • 7.8 Russia
      • 7.9 Spain
      • 7.10 Key Economic Indicators of Few Europe Countries

      8 Middle East & Africa

      • 8.1 Middle East & Africa Acinetobacter Infections Treatment by Countries
        • 8.1.1 Middle East & Africa Acinetobacter Infections Treatment Consumption by Countries (2014-2019)
        • 8.1.2 Middle East & Africa Acinetobacter Infections Treatment Value by Countries (2014-2019)
      • 8.2 Middle East & Africa Acinetobacter Infections Treatment Consumption by Type
      • 8.3 Middle East & Africa Acinetobacter Infections Treatment Consumption by Application
      • 8.4 Egypt
      • 8.5 South Africa
      • 8.6 Israel
      • 8.7 Turkey
      • 8.8 GCC Countries

      9 Market Drivers, Challenges and Trends

      • 9.1 Market Drivers and Impact
        • 9.1.1 Growing Demand from Key Regions
        • 9.1.2 Growing Demand from Key Applications and Potential Industries
      • 9.2 Market Challenges and Impact
      • 9.3 Market Trends

      10 Marketing, Distributors and Customer

      • 10.1 Sales Channel
        • 10.1.1 Direct Channels
        • 10.1.2 Indirect Channels
      • 10.2 Acinetobacter Infections Treatment Distributors
      • 10.3 Acinetobacter Infections Treatment Customer

      11 Global Acinetobacter Infections Treatment Market Forecast

      • 11.1 Global Acinetobacter Infections Treatment Consumption Forecast (2019-2024)
      • 11.2 Global Acinetobacter Infections Treatment Forecast by Regions
        • 11.2.1 Global Acinetobacter Infections Treatment Forecast by Regions (2019-2024)
        • 11.2.2 Global Acinetobacter Infections Treatment Value Forecast by Regions (2019-2024)
        • 11.2.3 Americas Consumption Forecast
        • 11.2.4 APAC Consumption Forecast
        • 11.2.5 Europe Consumption Forecast
        • 11.2.6 Middle East & Africa Consumption Forecast
      • 11.3 Americas Forecast by Countries
        • 11.3.1 United States Market Forecast
        • 11.3.2 Canada Market Forecast
        • 11.3.3 Mexico Market Forecast
        • 11.3.4 Brazil Market Forecast
      • 11.4 APAC Forecast by Countries
        • 11.4.1 China Market Forecast
        • 11.4.2 Japan Market Forecast
        • 11.4.3 Korea Market Forecast
        • 11.4.4 Southeast Asia Market Forecast
        • 11.4.5 India Market Forecast
        • 11.4.6 Australia Market Forecast
      • 11.5 Europe Forecast by Countries
        • 11.5.1 Germany Market Forecast
        • 11.5.2 France Market Forecast
        • 11.5.3 UK Market Forecast
        • 11.5.4 Italy Market Forecast
        • 11.5.5 Russia Market Forecast
        • 11.5.6 Spain Market Forecast
      • 11.6 Middle East & Africa Forecast by Countries
        • 11.6.1 Egypt Market Forecast
        • 11.6.2 South Africa Market Forecast
        • 11.6.3 Israel Market Forecast
        • 11.6.4 Turkey Market Forecast
        • 11.6.5 GCC Countries Market Forecast
      • 11.7 Global Acinetobacter Infections Treatment Forecast by Type
      • 11.8 Global Acinetobacter Infections Treatment Forecast by Application

      12 Key Players Analysis

      • 12.1 Entasis Therapeutics
        • 12.1.1 Company Details
        • 12.1.2 Acinetobacter Infections Treatment Product Offered
        • 12.1.3 Entasis Therapeutics Acinetobacter Infections Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.1.4 Main Business Overview
        • 12.1.5 Entasis Therapeutics News
      • 12.2 Roche
        • 12.2.1 Company Details
        • 12.2.2 Acinetobacter Infections Treatment Product Offered
        • 12.2.3 Roche Acinetobacter Infections Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.2.4 Main Business Overview
        • 12.2.5 Roche News
      • 12.3 Adenium Biotech
        • 12.3.1 Company Details
        • 12.3.2 Acinetobacter Infections Treatment Product Offered
        • 12.3.3 Adenium Biotech Acinetobacter Infections Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.3.4 Main Business Overview
        • 12.3.5 Adenium Biotech News
      • 12.4 Vaxdyn
        • 12.4.1 Company Details
        • 12.4.2 Acinetobacter Infections Treatment Product Offered
        • 12.4.3 Vaxdyn Acinetobacter Infections Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.4.4 Main Business Overview
        • 12.4.5 Vaxdyn News
      • 12.5 Hsiri Therapeutics
        • 12.5.1 Company Details
        • 12.5.2 Acinetobacter Infections Treatment Product Offered
        • 12.5.3 Hsiri Therapeutics Acinetobacter Infections Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.5.4 Main Business Overview
        • 12.5.5 Hsiri Therapeutics News
      • 12.6 Aridis Pharmaceuticals
        • 12.6.1 Company Details
        • 12.6.2 Acinetobacter Infections Treatment Product Offered
        • 12.6.3 Aridis Pharmaceuticals Acinetobacter Infections Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.6.4 Main Business Overview
        • 12.6.5 Aridis Pharmaceuticals News
      • 12.7 LegoChem Biosciences
        • 12.7.1 Company Details
        • 12.7.2 Acinetobacter Infections Treatment Product Offered
        • 12.7.3 LegoChem Biosciences Acinetobacter Infections Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.7.4 Main Business Overview
        • 12.7.5 LegoChem Biosciences News
      • 12.8 Atterx Biotherapeutics
        • 12.8.1 Company Details
        • 12.8.2 Acinetobacter Infections Treatment Product Offered
        • 12.8.3 Atterx Biotherapeutics Acinetobacter Infections Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.8.4 Main Business Overview
        • 12.8.5 Atterx Biotherapeutics News
      • 12.9 Achaogen
        • 12.9.1 Company Details
        • 12.9.2 Acinetobacter Infections Treatment Product Offered
        • 12.9.3 Achaogen Acinetobacter Infections Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.9.4 Main Business Overview
        • 12.9.5 Achaogen News
      • 12.10 Peptilogics
        • 12.10.1 Company Details
        • 12.10.2 Acinetobacter Infections Treatment Product Offered
        • 12.10.3 Peptilogics Acinetobacter Infections Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.10.4 Main Business Overview
        • 12.10.5 Peptilogics News
      • 12.11 Sealife PHARMA
      • 12.12 Shionogi
      • 12.13 Techulon
      • 12.14 Tetraphase Pharmaceuticals

      13 Research Findings and Conclusion

      Acinetobacter is a group of bacteria commonly found in soil and water. While there are many types or “species” of Acinetobacter and all can cause human disease, Acinetobacter baumannii accounts for about 80% of reported infections.

      Outbreaks of Acinetobacter infections typically occur in intensive care units and healthcare settings housing very ill patients. Acinetobacter infections rarely occur outside of healthcare settings.

      Acinetobacter is often resistant to many commonly prescribed antibiotics. Decisions on treatment of infections with Acinetobacter should be made on a case-by-case basis by a healthcare provider. Acinetobacter infection typically occurs in ill patients and can either cause or contribute to death in these patients.

      In the last several years, global market of Acinetobacter Infections Treatment developed rapidly, with an average growth rate of 2.96%. In 2016, United States Market Size of Acinetobacter Infections Treatment is nearly 22 M USD. For developing product, there are 1 in Phase III, 1 in Phase Ⅱ, 4 in Phase 1 and 8 in Preclinical. The total investment for Acinetobacter Infections Treatmen Drugs developing is around 90 M USD.
      The global average Cost of Acinetobacter Infections Treatment is in the decreasing trend, from 2901 USD/Case in 2012 to2870 USD/Case in 2016. With the situation of global economy, prices will be in decreasing trend in the following five years.
      The classification of Acinetobacter Infections Treatment includes Sulbactam, Carbapenems , Aminoglycosides, Polymyxins, Tigecycline and Others Treatment, and the proportion of Aminoglycosides in 2016 is about 18%, and the proportion is in decreasing trend from 2012 to 2016.

      According to this study, over the next five years the Acinetobacter Infections Treatment market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Acinetobacter Infections Treatment business, shared in Chapter 3.

      This report presents a comprehensive overview, market shares, and growth opportunities of Acinetobacter Infections Treatment market by product type, application, key manufacturers and key regions and countries.

      This study considers the Acinetobacter Infections Treatment value and volume generated from the sales of the following segments:

      Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
      Sulbactam
      Carbapenems
      Aminoglycosides
      Polymyxins
      Tetracyclines
      Others
      Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
      Application I
      Application II

      This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
      Americas
      United States
      Canada
      Mexico
      Brazil
      APAC
      China
      Japan
      Korea
      Southeast Asia
      India
      Australia
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Middle East & Africa
      Egypt
      South Africa
      Israel
      Turkey
      GCC Countries

      The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
      Entasis Therapeutics
      Roche
      Adenium Biotech
      Vaxdyn
      Hsiri Therapeutics
      Aridis Pharmaceuticals
      LegoChem Biosciences
      Atterx Biotherapeutics
      Achaogen
      Peptilogics
      Sealife PHARMA
      Shionogi
      Techulon
      Tetraphase Pharmaceuticals

      In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

      Research objectives
      To study and analyze the global Acinetobacter Infections Treatment consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
      To understand the structure of Acinetobacter Infections Treatment market by identifying its various subsegments.
      Focuses on the key global Acinetobacter Infections Treatment manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
      To analyze the Acinetobacter Infections Treatment with respect to individual growth trends, future prospects, and their contribution to the total market.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      To project the consumption of Acinetobacter Infections Treatment submarkets, with respect to key regions (along with their respective key countries).
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
      To strategically profile the key players and comprehensively analyze their growth strategies.

      Buy now